Suchergebnisse - "Zhong, Nanshan"

PubPharm (9)

1

TIOtropium Safety and Performance In Respimat® (TIOSPIRTM ) : Analysis of Asian cohort of COPD patients

enthalten in: Respirology (Carlton, Vic.) | 2016

von Zhong, N. | Moon, H. | Lee, K. | +7

CommentIn: Respirology. 2016 Nov;21(8):1340-1341. - PMID 27677257

2

Effect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease : a 26-week Asia-Pacific study

enthalten in: Respirology (Carlton, Vic.) | 2014

von Yao, W. | Wang, C. | Zhong, N. | +7

3

Effects of nebulized high-dose budesonide on moderate-to-severe acute exacerbation of asthma in children : a randomized, double-blind, placebo-controlled study

enthalten in: Respirology (Carlton, Vic.) | 2013

von Chen, A. | Zeng, G. | Chen, R. | +5

4

Non-smoking-related chronic obstructive pulmonary disease : a neglected entity?

enthalten in: Respirology (Carlton, Vic.) | 2012

von Zeng, G. | Sun, B. | Zhong, N.

5

Outdoor air pollution and respiratory health in Asia

enthalten in: Respirology (Carlton, Vic.) | 2011

von Chung, K. | Zhang, J. | Zhong, N.

6

Chronic obstructive pulmonary disease in the absence of chronic bronchitis in China

enthalten in: Respirology (Carlton, Vic.) | 2010

von Lu, M. | Yao, W. | Zhong, N. | +14

CommentIn: Respirology. 2011 Apr;16(3):574. - PMID 21261782

7

Genetic analysis of CC16, OGG1 and GCLC polymorphisms and susceptibility to COPD

enthalten in: Respirology (Carlton, Vic.) | 2007

von Liu, S. | Li, B. | Zhou, Y. | +2

ErratumIn: Respirology. 2007 May;12(3):465

8

Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year

enthalten in: Respirology (Carlton, Vic.) | 2006

von Zhou, Y. | Wang, X. | Zeng, X. | +6

9

Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance

enthalten in: Respirology (Carlton, Vic.) | 2006

von Mo, H. | Zeng, G. | Ren, X. | +8

1
[1]